Hemoglobinopathies Market Size, Share & Trends Report

Hemoglobinopathies Market Size, Share & Trends Analysis Report By Type (Thalassemia, Sickle Cell Disease, Other Hemoglobin (Hb) Variants), By Diagnosis, By Therapy, By Region, And Segment Forecasts, 2023 - 2030

  • Report ID: 978-1-68038-736-0
  • Number of Report Pages: 150
  • Format: PDF, Horizon Databook
  • Historical Range: 2018 - 2021
  • Forecast Period: 2023 - 2030 
  • Industry: Healthcare

Table of Contents

Chapter 1. Hemoglobinopathies Market: Methodology and Scope
                   1.1. Market Segmentation and Scope
                       1.1.1. Segment Definitions
                           1.1.1.1. Type segment
                           1.1.1.2. Diagnosis segment
                           1.1.1.3. Therapy segment
                   1.2. Regional Scope
                   1.3. Estimates and Forecast Timeline
                   1.4. Objectives
                       1.4.1. Objective - 1
                       1.4.2. Objective - 2
                       1.4.3. Objective - 3
                   1.5. Research Methodology
                   1.6. Information Procurement
                       1.6.1. Purchased Database
                       1.6.2. GVR’s Internal Database
                       1.6.3. Secondary Sources
                       1.6.4. Primary research
                   1.7. Information or Data Analysis
                       1.7.1. Data Analysis Models
                   1.8. Market Formulation & Validation
                   1.9. Model Details
                       1.9.1. Commodity Flow Analysis
                   1.10. List of Secondary Sources
                   1.11. List of Abbreviations
Chapter 2. Hemoglobinopathies Market: Executive Summary
                   2.1. Market Snapshot
                   2.2. Type Snapshot
                   2.3. Diagnosis and Therapy Snapshot
                   2.4. Competitive Landscape Snapshot
Chapter 3. Hemoglobinopathies Market: Variables, Trends, & Scope
                   3.1. Market Lineage Outlook
                       3.1.1. Parent Market Outlook
                       3.1.2. Related/Ancillary Market Outlook
                   3.2. Market Dynamics
                       3.2.1. Market Driver Analysis
                           3.2.1.1. Increasing prevalence of hemoglobinopathies in under - developed countries
                           3.2.1.2. High unmet needs
                           3.2.1.3. Increasing R&D investments
                           3.2.1.4. Initiatives to improve disease awareness levels
                       3.2.2. Market Restraint Analysis
                           3.2.2.1. Lack of healthcare infrastructure
                           3.2.2.2. High cost of treatment
                   3.3. Industry Analysis Tools
                       3.3.1. Porter’s Five Forces Analysis
                       3.3.2. PESTEL Analysis
                       3.3.3. COVID - 19 Impact Analysis
Chapter 4. Type Business Analysis
                   4.1. Hemoglobinopathies Market: Type Movement Analysis
                   4.2. Thalassemia
                       4.2.1. Thalassemia Market, 2018 - 2030 (USD Million)
                   4.3. Sickle Cell Disease
                       4.3.1. Sickle Cell Disease Market, 2018 - 2030 (USD Million)
                   4.4. Hb Variants
                       4.4.1. Hb Variants Market, 2018 - 2030 (USD Million)
Chapter 5. Diagnosis Business Analysis
                   5.1. Hemoglobinopathies Market: Diagnosis Movement Analysis
                   5.2. Thalassemia
                       5.2.1. Thalassemia Market, 2018 - 2030 (USD Million)
                   5.3. Sickle Cell Disease
                       5.3.1. Sickle Cell Disease Market, 2018 - 2030 (USD Million)
                   5.4. Hb Variants
                       5.4.1. Hb Variants Market, 2018 - 2030 (USD Million)
Chapter 6. Therapy Business Analysis
                   6.1. Hemoglobinopathies Market: Therapy Movement Analysis
                   6.2. Thalassemia
                       6.2.1. Thalassemia Market, 2018 - 2030 (USD Million)
                   6.3. Sickle Cell Disease
                       6.3.1. Sickle Cell Disease Market, 2018 - 2030 (USD Million)
                   6.4. Other Hb Variants
                       6.4.1. Other Hb Variants Market, 2018 - 2030 (USD Million)
Chapter 7. Regional Business Analysis
                   7.1. Hemoglobinopathies Market Share By Region, 2022 & 2030
                   7.2. North America
                       7.2.1. SWOT Analysis
                       7.2.2. North America Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.2.3. U.S.
                           7.2.3.1. Key Country Dynamics
                           7.2.3.2. Target Disease Prevalence
                           7.2.3.3. Competitive Scenario
                           7.2.3.4. Regulatory Framework
                           7.2.3.5. U.S. Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.2.4. Canada
                           7.2.4.1. Key Country Dynamics
                           7.2.4.2. Target Disease Prevalence
                           7.2.4.3. Competitive Scenario
                           7.2.4.4. Regulatory Framework
                           7.2.4.5. Canada Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                   7.3. Europe
                       7.3.1. Europe Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.3.2. UK
                           7.3.2.1. Key Country Dynamics
                           7.3.2.2. Target Disease Prevalence
                           7.3.2.3. Competitive Scenario
                           7.3.2.4. Regulatory Framework
                           7.3.2.5. UK Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.3.3. Germany
                           7.3.3.1. Key Country Dynamics
                           7.3.3.2. Target Disease Prevalence
                           7.3.3.3. Competitive Scenario
                           7.3.3.4. Regulatory Framework
                           7.3.3.5. Germany Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.3.4. France
                           7.3.4.1. Key Country Dynamics
                           7.3.4.2. Target Disease Prevalence
                           7.3.4.3. Competitive Scenario
                           7.3.4.4. Regulatory Framework
                           7.3.4.5. France Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.3.5. Italy
                           7.3.5.1. Key Country Dynamics
                           7.3.5.2. Target Disease Prevalence
                           7.3.5.3. Competitive Scenario
                           7.3.5.4. Regulatory Framework
                           7.3.5.5. Italy Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.3.6. Spain
                           7.3.6.1. Key Country Dynamics
                           7.3.6.2. Target Disease Prevalence
                           7.3.6.3. Competitive Scenario
                           7.3.6.4. Regulatory Framework
                           7.3.6.5. Spain Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.3.7. Denmark
                           7.3.7.1. Key Country Dynamics
                           7.3.7.2. Target Disease Prevalence
                           7.3.7.3. Competitive Scenario
                           7.3.7.4. Regulatory Framework
                           7.3.7.5. Denmark Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.3.8. Sweden
                           7.3.8.1. Key Country Dynamics
                           7.3.8.2. Target Disease Prevalence
                           7.3.8.3. Competitive Scenario
                           7.3.8.4. Regulatory Framework
                           7.3.8.5. Sweden Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.3.9. Norway
                           7.3.9.1. Key Country Dynamics
                           7.3.9.2. Target Disease Prevalence
                           7.3.9.3. Competitive Scenario
                           7.3.9.4. Regulatory Framework
                           7.3.9.5. Norway Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.3.10. Russia
                           7.3.10.1. Key Country Dynamics
                           7.3.10.2. Target Disease Prevalence
                           7.3.10.3. Competitive Scenario
                           7.3.10.4. Regulatory Framework
                           7.3.10.5. Russia Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                   7.4. Asia Pacific
                       7.4.1. Asia Pacific Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.4.2. Japan
                           7.4.2.1. Key Country Dynamics
                           7.4.2.2. Target Disease Prevalence
                           7.4.2.3. Competitive Scenario
                           7.4.2.4. Regulatory Framework
                           7.4.2.5. Japan Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.4.3. China
                           7.4.3.1. Key Country Dynamics
                           7.4.3.2. Target Disease Prevalence
                           7.4.3.3. Competitive Scenario
                           7.4.3.4. Regulatory Framework
                           7.4.3.5. China Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.4.4. India
                           7.4.4.1. Key Country Dynamics
                           7.4.4.2. Target Disease Prevalence
                           7.4.4.3. Competitive Scenario
                           7.4.4.4. Regulatory Framework
                           7.4.4.5. India Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.4.5. Australia
                           7.4.5.1. Key Country Dynamics
                           7.4.5.2. Target Disease Prevalence
                           7.4.5.3. Competitive Scenario
                           7.4.5.4. Regulatory Framework
                           7.4.5.5. Australia Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.4.6. Thailand
                           7.4.6.1. Key Country Dynamics
                           7.4.6.2. Target Disease Prevalence
                           7.4.6.3. Competitive Scenario
                           7.4.6.4. Regulatory Framework
                           7.4.6.5. Thailand Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.4.7. South Korea
                           7.4.7.1. Key Country Dynamics
                           7.4.7.2. Target Disease Prevalence
                           7.4.7.3. Competitive Scenario
                           7.4.7.4. Regulatory Framework
                           7.4.7.5. South Korea Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.4.8. Singapore
                           7.4.8.1. Key Country Dynamics
                           7.4.8.2. Target Disease Prevalence
                           7.4.8.3. Competitive Scenario
                           7.4.8.4. Regulatory Framework
                           7.4.8.5. Singapore Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                   7.5. Latin America
                       7.5.1. Latin America Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.5.2. Brazil
                           7.5.2.1. Key Country Dynamics
                           7.5.2.2. Target Disease Prevalence
                           7.5.2.3. Competitive Scenario
                           7.5.2.4. Regulatory Framework
                           7.5.2.5. Brazil Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.5.3. Mexico
                           7.5.3.1. Key Country Dynamics
                           7.5.3.2. Target Disease Prevalence
                           7.5.3.3. Competitive Scenario
                           7.5.3.4. Regulatory Framework
                           7.5.3.5. Mexico Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.5.4. Argentina
                           7.5.4.1. Key Country Dynamics
                           7.5.4.2. Target Disease Prevalence
                           7.5.4.3. Competitive Scenario
                           7.5.4.4. Regulatory Framework
                           7.5.4.5. Argentina Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                   7.6. MEA
                       7.6.1. MEA Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.6.2. South Africa
                           7.6.2.1. Key Country Dynamics
                           7.6.2.2. Target Disease Prevalence
                           7.6.2.3. Competitive Scenario
                           7.6.2.4. Regulatory Framework
                           7.6.2.5. South Africa Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.6.3. Saudi Arabia
                           7.6.3.1. Key Country Dynamics
                           7.6.3.2. Target Disease Prevalence
                           7.6.3.3. Competitive Scenario
                           7.6.3.4. Regulatory Framework
                           7.6.3.5. Saudi Arabia Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.6.4. UAE
                           7.6.4.1. Key Country Dynamics
                           7.6.4.2. Target Disease Prevalence
                           7.6.4.3. Competitive Scenario
                           7.6.4.4. Regulatory Framework
                           7.6.4.5. UAE Hemoglobinopathies Market, 2018 - 2030 (USD Million)
                       7.6.5. Kuwait
                           7.6.5.1. Key Country Dynamics
                           7.6.5.2. Target Disease Prevalence
                           7.6.5.3. Competitive Scenario
                           7.6.5.4. Regulatory Framework
                           7.6.5.5. Kuwait Hemoglobinopathies Market, 2018 - 2030 (USD Million)
Chapter 8. Competitive Landscape
                   8.1. Participant Categorization
                       8.1.1. Sangamo Therapeutics
                           8.1.1.1. Overview
                           8.1.1.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.1.1.3. Product Benchmarking
                           8.1.1.4. Strategic Initiatives
                       8.1.2. Bluebird bio, Inc.
                           8.1.2.1. Overview
                           8.1.2.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.1.2.3. Product Benchmarking
                           8.1.2.4. Strategic Initiatives
                       8.1.3. Global Blood Therapeutics, Inc
                           8.1.3.1. Overview
                           8.1.3.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.1.3.3. Product Benchmarking
                           8.1.3.4. Strategic Initiatives
                       8.1.4. Pfizer, Inc.
                           8.1.4.1. Overview
                           8.1.4.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.1.4.3. Product Benchmarking
                           8.1.4.4. Strategic Initiatives
                       8.1.5. Emmaus Life Sciences, Inc.
                           8.1.5.1. Overview
                           8.1.5.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.1.5.3. Product Benchmarking
                           8.1.5.4. Strategic Initiatives
                       8.1.6. Prolong Pharmaceuticals, LLC
                           8.1.6.1. Overview
                           8.1.6.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.1.6.3. Product Benchmarking
                           8.1.6.4. Strategic Initiatives
                       8.1.7. Celgene Corporation (BMS)
                           8.1.7.1. Overview
                           8.1.7.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.1.7.3. Product Benchmarking
                           8.1.7.4. Strategic Initiatives
                       8.1.8. Bioverativ, Inc. (Sanofi)
                           8.1.8.1. Overview
                           8.1.8.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.1.8.3. Product Benchmarking
                           8.1.8.4. Strategic Initiatives
                       8.1.9. Gamida Cell
                           8.1.9.1. Overview
                           8.1.9.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.1.9.3. Product Benchmarking
                           8.1.9.4. Strategic Initiatives
                       8.1.10. Novartis AG
                           8.1.10.1. Overview
                           8.1.10.2. Financial Performance (Net Revenue/Sales/EBITDA/Gross Profit)
                           8.1.10.3. Product Benchmarking
                           8.1.10.4. Strategic Initiatives
                   8.2. Participant’s Overview
                   8.3. Financial Performance
                   8.4. Product Benchmarking
                   8.5. Company Market Share Analysis, 2022
                   8.6. Strategy Mapping
                       8.6.1. Expansion
                       8.6.2. Acquisition
                       8.6.3. Product/Service Launch
                       8.6.4. Others
Chapter 9. Analyst View


List of Tables

Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 4 Global hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 5 Global hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 6 Global hemoglobinopathies market, by region, 2018 - 2030 (USD Million)
Table 7 North America hemoglobinopathies market, by country, 2018 - 2030 (USD Million)
Table 8 North America hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 9 North America hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 10 North America hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 11 U.S. hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 12 U.S. hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 13 U.S. hemoglobinopathies Market, by therapy, 2018 - 2030 (USD Million)
Table 14 Canada hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 15 Canada hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 16 Canada hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 17 Europe hemoglobinopathies market, by country, 2018 - 2030 (USD Million)
Table 18 Europe hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 19 Europe hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 20 Europe hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 21 UK hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 22 UK hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 23 UK hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 24 Germany hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 25 Germany hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 26 Germany hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 27 France hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 28 France hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 29 France hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 30 Italy hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 31 Italy hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 32 Italy hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 33 Spain hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 34 Spain hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 35 Spain hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 36 Denmark hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 37 Denmark hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 38 Denmark hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 39 Sweden hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 40 Sweden hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 41 Sweden hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 42 Norway hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 43 Norway hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 44 Norway hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 45 Asia Pacific hemoglobinopathies market, by country, 2018 - 2030 (USD Million)
Table 46 Asia Pacific hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 47 Asia Pacific hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 48 Asia Pacific hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 49 Japan hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 50 Japan hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 51 Japan hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 52 China hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 53 China hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 54 China hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 55 India hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 56 India hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 57 India hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 58 South Korea hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 59 South Korea hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 60 South Korea hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 61 Australia hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 62 Australia hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 63 Australia hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 64 Singapore hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 65 Singapore hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 66 Singapore hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 67 Thailand hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 68 Thailand hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 69 Thailand hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 70 Latin America hemoglobinopathies market, by country, 2018 - 2030 (USD Million)
Table 71 Latin America hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 72 Latin America hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 73 Latin America hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 74 Brazil hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 75 Brazil hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 76 Brazil hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 77 Mexico hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 78 Mexico hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 79 Mexico hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 80 Argentina hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 81 Argentina hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 82 Argentina hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 83 Middle East & Africa hemoglobinopathies market, by country, 2018 - 2030 (USD Million)
Table 84 Middle East & Africa hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 85 Middle East & Africa hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 86 Middle East & Africa hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 87 South Africa hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 88 South Africa hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 89 South Africa hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 90 UAE hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 91 UAE hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 92 UAE hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 93 Saudi Arabia hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 94 Saudi Arabia hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 95 Saudi Arabia hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 96 Kuwait hemoglobinopathies market, by type, 2018 - 2030 (USD Million)
Table 97 Kuwait hemoglobinopathies market, by diagnosis, 2018 - 2030 (USD Million)
Table 98 Kuwait hemoglobinopathies market, by therapy, 2018 - 2030 (USD Million)
Table 99 Company Overview
Table 100 Financial Performance
Table 101 Product Benchmarking
Table 102 Strategic Initiatives


List of Figures

Fig. 1 Hemoglobinopathies market segmentation
Fig. 2 Market research process
Fig. 3 Information procurement
Fig. 4 Primary research pattern
Fig. 5 Market research approaches
Fig. 6 Value chain - based sizing & forecasting
Fig. 7 Market formulation & validation
Fig. 8 Hemoglobinopathies market segmentation
Fig. 9 Market snapshot, 2022
Fig. 10 Market trends & outlook
Fig. 11 Market driver relevance analysis (current & future impact)
Fig. 12 Market restraint relevance analysis (current & future impact)
Fig. 13 PESTEL analysis
Fig. 14 Porter’s five forces analysis
Fig. 15 Global Hemoglobinopathies market: Type movement analysis
Fig. 16 Global Hemoglobinopathies market, for thalassemia, 2018 - 2030 (USD Million)
Fig. 17 Global Hemoglobinopathies market, for sickle cell disease, 2018 - 2030 (USD Million)
Fig. 18 Global Hemoglobinopathies market, for Hb variants, 2018 - 2030 (USD Million)
Fig. 19 Global Hemoglobinopathies market: Diagnosis movement analysis
Fig. 20 Global Hemoglobinopathies market, for thalassemia, 2018 - 2030 (USD Million)
Fig. 21 Global Hemoglobinopathies market, for sickle cell disease, 2018 - 2030 (USD Million)
Fig. 22 Global Hemoglobinopathies market, for Hb variants, 2018 - 2030 (USD Million)
Fig. 23 Global Hemoglobinopathies market: Therapy movement analysis
Fig. 24 Global Hemoglobinopathies market, for thalassemia, 2018 - 2030 (USD Million)
Fig. 25 Global Hemoglobinopathies market, for sickle cell disease, 2018 - 2030 (USD Million)
Fig. 26 Global Hemoglobinopathies market, for other Hb variants, 2018 - 2030 (USD Million)
Fig. 27 Regional marketplace: Key takeaways
Fig. 28 Regional outlook, 2022 & 2030
Fig. 29 Global Hemoglobinopathies market: Region movement analysis
Fig. 30 North America Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 31 U.S. Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 32 Canada Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 33 Europe Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 34 Germany Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 35 UK Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 36 France Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 37 Italy Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 38 Spain Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 39 Denmark Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 40 Sweden Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 41 Norway Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 42 Asia Pacific Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 43 Japan Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 44 China Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 45 India Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 46 Australia Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 47 South Korea Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 48 Thailand Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 49 Singapore Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 50 Latin America Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 51 Brazil Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 52 Mexico Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 53 Argentina Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 54 Middle East and Africa Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 55 South Africa Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 56 Saudi Arabia Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 57 UAE Hemoglobinopathies market, 2018 - 2030 (USD Million)
Fig. 58 Kuwait Hemoglobinopathies market, 2018 - 2030 (USD Million)

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

ISO

ISO Certified

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon